Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

An in-house real-time polymerase chain reaction: standardisation and comparison with the Cobas Amplicor HBV monitor and Cobas AmpliPrep/Cobas TaqMan HBV tests for the quantification of hepatitis B virus DNA

Full text
Author(s):
de Torres Santos, Ana Paula [1] ; Levi, Jose Eduardo [2] ; Lemos, Marcilio Figueiredo [3] ; Calux, Samira Julien [3] ; Oba, Isabel Takano [3] ; Moreira, Regina Celia [3]
Total Authors: 6
Affiliation:
[1] Univ Sao Paulo, Fac Med, Hosp Clin, Div Lab Cent, Lab Imunol, Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, SP - Brazil
[3] Adolfo Lutz Inst, Ctr Virol, Nucleo Doencas Sanguineas & Sexuais, Sao Paulo, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Memórias do Instituto Oswaldo Cruz; v. 111, n. 2, p. 134-140, FEB 2016.
Web of Science Citations: 0
Abstract

This study aimed to standardise an in-house real-time polymerase chain reaction (rtPCR) to allow quantification of hepatitis B virus (HBV) DNA in serum or plasma samples, and to compare this method with two commercial assays, the Cobas Amplicor HBV monitor and the Cobas AmpliPrep/Cobas TaqMan HBV test. Samples from 397 patients from the state of São Paulo were analysed by all three methods. Fifty-two samples were from patients who were human immunodeficiency virus and hepatitis C virus positive, but HBV negative. Genotypes were characterised, and the viral load was measure in each sample. The in-house rtPCR showed an excellent success rate compared with commercial tests; inter-assay and intra-assay coefficients correlated with commercial tests (r = 0.96 and r = 0.913, p < 0.001) and the in-house test showed no genotype-dependent differences in detection and quantification rates. The in-house assay tested in this study could be used for screening and quantifying HBV DNA in order to monitor patients during therapy. (AU)

FAPESP's process: 09/53086-4 - Standardization and implantation of the real time PCR for detection and quantification of hepatitis B virus
Grantee:Regina Célia Moreira
Support Opportunities: Research Grants - Research in Public Policies for the National Health Care System (PP-SUS)